NanoViricides Inc. reported its financial results for the fiscal year ended June 30, 2025. The biopharmaceutical company reported no revenues for both the current and prior fiscal years. Net losses continued as the company has not commenced revenue-generating operations. Research and development expenses increased to $5.549 million for the year ended June 30, 2025, compared to $5.437 million for the year ended June 30, 2024. The increase of $0.112 million was mainly attributed to higher outside laboratory fees related to the preparation of Phase II clinical trial applications. NanoViricides stated its ongoing focus is on advancing drug candidates through preclinical studies and preparing for future clinical trials, with the goal of developing antiviral therapies using nanomedicine approaches. The company noted the potential for future developments in the antiviral field to impact its business plan and market opportunities.